Cell 2009,139(5):871–890.PubMedCrossRef 104. Moreb JS: Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 2008, 3:237–246.PubMedCrossRef 105. Glinsky GV, Olga Berezovska O, Glinskii AB: Microarray analysis identifies a death from cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115:1503–1521.PubMedCrossRef 106. Shi J, Zhou Z, Di W, Li N: Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC
Cancer 2013, 13:182.PubMedCrossRef 107. Rosanò L, Cianfrocca R, Spinella F, Di Proteases inhibitor Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A: Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011,17(8):2350–60.PubMedCrossRef 108. Tilly JL, Rueda BR: Minireview: stem cell contribution to ovarian development, function, and disease. Endocrinology 2008, 149:4307–4311.PubMedCrossRef EPZ015938 in vivo 109. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008,5(12):e232.PubMedCrossRef
110. Lawrenson K, Gayther SA: Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med 2009, 6:e25.PubMedCrossRef 111. Tothill IE: Biosensors for cancer markers p53 activator diagnosis. Semin Cell Dev Biol 2009, 20:55–62.PubMedCrossRef 112. Landen CN Jr, Goodman B, Katre AA, Steg
AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Immune system Jr, Coleman RL, Lopez-Berestein G, Sood AK: Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010,9(12):3186–3199.PubMedCrossRef 113. Wani AA, Sharma N, Shouche YS, Bapat SA: Nuclear-mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells. Oncogene 2006, 25:6336–6344.PubMedCrossRef 114. Frosina G: DNA repair in normal and cancer stem cells, with special reference to the central nervous system. Curr Med Chem 2009, 16:854–866.PubMedCrossRef 115. Lee AS, Kahatapitiya P, Kramer B, Joya JE, Hook J, Liu R, Schevzov G, Alexander IE, McCowage G, Montarras D, Gunning PW, Hardeman EC: Methylguanine DNA methyltransferase-mediated drug resistance-based selective enrichment and engraftment of transplanted stem cells in skeletal muscle. Stem Cells 2009, 27:1098–1108.PubMedCrossRef 116. Clarke-Pearson DL: Clinical practice–screening for ovarian cancer. N Engl J Med 2009, 361:170–177.PubMedCrossRef 117. Schwartz PE: Neoadjuvant chemotherapy for the management of ovarian cancer. Best Practice & Research. Clin Obstet Gynaecol 2002, 16:585–596. 118. Phillips TM, McBride WH, Pajonk F: The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777–1785.